Table 3 Summary of studies of dry powder measles product presented to the expert group for stage II of the CHNRI process
Reference | Factor for investigation | Results | Conclusions |
|---|---|---|---|
LiCalsi, C., et al [55] | Feasibility of dry powder inhalation in measles | Optimal vaccine delivery site – lungs; Particle sizing 1-5μm; Preparation – micronization and jet-milling ;3 Spiros delivery devices designed | Undemonstrable clinical application |
de Swart, R.L., et al [56] | Dry powder vaccination in Macaques | Low seroresponse to measles dry powder blend compared to injection or liquid aerosol vaccination | Proof of principle evident by stimulation of weak immune response. Poor device design in macaque model – loss of vaccine at delivery. |
LiCalsi, C., et al [57] | Dry powder measles vaccine potency retention | Up to 89% viral potency retention can be achieved with micronization. | |
Burger, J.L., et al [58] | Stabilizing dry powder measles formulations | Myo-inositol> trehalose as a sugar stabilizer in dry powder measles vaccinations | Myo-inositol is relatively unhygroscopic, improving its dry powder vaccination credentials |